Advertisement

CanSino's COVID-19 Vaccine Was Just Approved for Limited Use in China. Here's What Investors Should Know.

CanSino's COVID-19 Vaccine Was Just Approved for Limited Use in China. Here's What Investors Should Know.

Despite a worldwide race to develop a COVID-19 vaccine, China's CanSino Biologics (SEHK: 6185) didn't make huge headlines when it announced last week that its COVID-19 vaccine candidate had been approved for widespread use among members of the Chinese military. Between the vaccine's small population of eligible recipients, its limited efficacy, and its intense side effects, nobody seems to be clamoring to license it for manufacturing outside China. CanSino's stock price has also remained shockingly unperturbed by the company's breakthrough.